Medical device company Thoratec (NSDQ:THOR) took a harsh blow from Wall Street after releasing its Q1 earnings report, with shares down more than 10% by mid-day.
Structural Heart
Abiomed gains on surging FY2013 profits
Abiomed (NSDQ:ABMD) shares gained nearly 7% this morning after the medical device company reported profit growth in excess of 900%, beating Wall Street’s earnings expectations along the way.
The Danvers, Mass.-based heart pump maker reported fiscal 2013 profits of $15.0 million, or 38¢ per share, on sales of $157.6 million, for a whopping bottom-line gain of 904.3% on top-line growth of 25.8%.
Abiomed: Costs of Impella heart pump come in well below national standards
Abiomed gains on preliminary Q4 sales numbers
Abiomed (NSDQ:ABMD) shares jumped nearly 9% yesterday after the medical device company reported double-digit sales growth during its fiscal 4th quarter and 2013.
Danvers, Mass.-based Abiomed said preliminary sales for the 3 months ended March 31 were $43.7 million, up 17% over the $37.3 million posted during Q4 2012.
Full-year sales rose 25% to $157.1 million, compared with $126.4 million during fiscal 2012, according to a press release.
Boston Scientific launches clinical trials for next-gen MRI-friendly pacemaker
Boston Scientific (NYSE:BSX) launched a new clinical trial assessing the performance of its next-generation ImageReady MRI-friendly pacemaker, designed to reduce interference while patients undergo an MRI.
Abiomed rebounds after 4% slide on Piper Jaffray downgrade | Wall Street Beat
Abiomed (NSDQ:ABMD) shares clawed back some of the nearly 4% lost yesterday as investors reacted to a downgrade by analysts at Piper Jaffray.
The Danvers, Mass.-based medical device company’s stock fell from a $17.20-per-share close April 8 to end yesterday at $16.52 per share, a more than 3.9% decline. ABMD shares were trading at $16.98 apiece as of about 11 this morning, however, up 2.8%.
Updated: Abiomed initiates trial of right-side heart pump
Syncardia nabs 2 Humanitarian Use Device wins for its smaller artificial heart
SynCardia Systems won 2 new Humanitarian Use Device designations for its 50cc Total Artificial Heart as a cardiac bridge transplant device.
The new HUD designations apply to use with children, smaller women and other people with small stature. The Tuscon, Ariz.-based device manufacturer designed this device as a smaller version of its 70cc temporary Total Artificial Heart, approved in 2004, according to a press release.
Thoratec touts 1st human use for catheter-based HeartMate PHP heart pump
Thoratec (NSDQ:THOR) touted the 1st human use of its HeartMate PHP device as a "milestone case" for the heart pump technology.
Dr. Adrian Ebner at Sanatorio Italiano in Asuncion, Paraguay, used HeartMate PHP to stabilize a patient for an hour on the operating table during a percutaneous coronary procedure. Two other patients were subsequently treated with the catheter-based heart pump.
Abiomed lands reimbursement expansion for Impella heart pump
Abiomed (NSDQ:ABMD) won expanded reimbursement for its flagship Impella heart pump from 4 private and Medicare Advantage insurers, including 1 of the largest names in the industry.
Humana, UnitedHealthcare Medicare Risk, Independence Blue Cross and Capital Blue Cross. The expanded coverage at the private or Medicare Advantage plans includes new Impella policies.
Do hybrid cars interfere with cardiac implants? Apparently not, study finds
In the 1st study of its kind to examine the interaction between hybrid cars and implantable cardiac devices, researchers found that the electromagnetic waves generated by the green vehicles don’t pose a threat.
"Hybrid cards do not generated clinically relevant amounts of [electromagnetic interference]," according to a team of researchers from the Mayo Clinic of Arizona. "It is safe for patients with ICD to interact with hybrid cars."